Sep 25, 2019 / 08:30AM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Allergy Therapeutics Company update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded. (Operator Instructions)
Manuel Llobet - Allergy Therapeutics plc - CEO & Executive Director
(technical difficulty)
today with me Nick Wykeman, and we'll share the year-end results.
So let's -- for those of you that are on the phone, we are starting straightforward into Page #5 of the presentation, the 3 pillars of growth. We've shown this slide sometimes. Sorry, yes, I said that it was well. So we've -- these are the 3 key areas of development of the company: developing the company in Europe, developing the pipeline and preparing for the U.S. entry.
If we go now to Page #7, we see how we have done in our first focus area, which is developing the company in Europe. It's been a good year. We have faced a more complex scenario this year, not only because of the Brexit preparations, we are the only competitor that have had to face that. But also, we
Full Year 2019 Allergy Therapeutics PLC Earnings Call Transcript
Sep 25, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers